Pharmacologic treatment of obsessive-compulsive disorder comorbidity

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 17, 2014, Pages 2543-2552

  Pallanti, Stefano ^a,b   Grassi, Giacomo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comorbidity; Obsessive compulsive disorder; Phase specific; Precision medicine; Treatment resistance

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; AMPHETAMINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CLOMIPRAMINE; CLOZAPINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMMUNOGLOBULIN; LAMOTRIGINE; LITHIUM; MEMANTINE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PENICILLIN DERIVATIVE; PIMOZIDE; PREGABALIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ADDICTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BODY DYSMORPHIC DISORDER; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; CYCLOTHYMIA; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG DEPENDENCE; EATING DISORDER; FUNCTIONAL DISEASE; HUMAN; IMPULSIVE DISORDER; LOW DRUG DOSE; MENTAL DISEASE; NEUROLOGIC DISEASE; OBSESSIVE COMPULSIVE DISORDER; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION; POSTINFECTION SYNDROME; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYMPTOM; TIC; TREATMENT RESPONSE; TRICHOTILLOMANIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMPLICATION; EATING DISORDERS; IMPULSE CONTROL DISORDERS; MOOD DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOLOGY; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; TICS;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD DEVELOPMENT DISORDERS, PERVASIVE; EATING DISORDERS; HUMANS; IMPULSE CONTROL DISORDERS; MOOD DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; TICS;

EID: 84910065201     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.964208     Document Type: Review

References (70)

1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010;15(1):53-63
2. de Mathis MA, Diniz JB, Hounie AG, et al. Trajectory in obsessive-compulsive disorder comorbidities. Eur Neuropsychopharmacol 2013;23:594-601
3. •• This is a relevant paper investigating the influence of comorbities on obsessive-compulsive disorder (OCD) course trajectory.
4. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessivecompulsive disorder. Expert Opin Emerg Drugs 2014;19(1):67-
5. Pallanti S, Hollander E, Bienstock C, International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5(2):181-91
6. Jakubovski E, Diniz JB, Valerio C, et al. Clinical predictors of long-term outcome in obsessive-compulsive disorder. Depress Anxiety 2013;30:763-72
7. Hofmeijer-Savink MK, van Oppen P, van Megen HJ, et al. Clinical relevance of comorbidity in obsessive-compulsive disorder: the Netherlands OCD Association Study. J Affect Diosrd 2013;150:847-54
8. • This is a relevant paper investigating in a large community sample the OCD comorbidities rates.
9. Pinto A, Mancebo MC, Eisen JL, et al. The brown longitudinal obsessive compulsive study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 2006;67(5):703-11
10. • This is a relevant paper investigating in a large community sample the OCD comorbidities rates.
11. Nestadt G, Di CZ, Riddle MA, et al. Obsessive-compulsive disorder: subclassification based on comorbidity. Psychol Med 2009;39:1491-501
12. •• This is a relevant paper proposing a subclassification of OCD based on comorbidity patterns.
13. Yaryura-Tobias JA. Nosological insertion of Axis I disorders in the etiology of obsessive compulsive disorder. J Anxiety Disord 2000;14(1):19-30
14. Pallanti S, Grassi G, Sarrecchia ED, et al. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry 2011;2:70
15. Valerio C, Diniz JB, de Mathis MA, et al. Does anti-obsessional pharmacotherapy treat so-called comorbid depressive and anxiety states? J Affect Disord 2012;139:187-92
16. • This is a relevant paper directly assessing the effects of anti-obsessional treatments on comorbid anxiety and mood symptoms.
17. Olatunji BO, Davis ML, Powers MB, Smits JA. Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. J Psychiatr Res 2013;47(1):33-41
18. Malhi GS, Hitching R, Berk M, et al. Pharmacological management of unipolar depression. Acta Psychiatr Scand 2013;127(443):6-23
19. Tükel R, Oflaz SB, Ozyildirim I, et al. Comparison of clinical characteristics in episodic and chronic obsessivecompulsive disorder. Depress Anxiety 2007;24(4):251-5
20. Amerio A, Odone A, Liapis CC, Ghaemi SN. Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Acta Psychiatr Scand 2014;129(5):343-58
21. Amerio A, Odone A, Marchesi C, Ghaemi SN. Treatment of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. J Affect Disord 2014;166:258-63
22. Berlim MT, Neufeld NH, Van den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory metaanalysis of randomized and sham-controlled trials. J Psychiatr Res 2013;47:999-1006
23. D'Ambrosio V, Albert U, Bogetto F, Maina G. Obsessive-compulsive disorder and cyclothymic temperament: an exploration of clinical features. J Affect Disord 2010;127(1-3):295-9
24. Parker G, McCraw S, Fletcher K. Cyclothymia. Depress Anxiety 2012;29(6):487-94
25. Manning JS, Haykal RF, Connor PD, et al. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament. J Affect Disord 2005;84(2-3):259-66
26. Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a doubleblind, placebo-controlled study. J Psychopharmacol 2012;26(11):1456-62
27. Torres AR, Ferrão YA, Shavitt RG, et al. Panic Disorder and Agoraphobia in OCD patients: clinical profile and possible treatment implications. Compr Psychiatry 2014;55(3):588-97
28. Savino M, Perugi G, Simonini E, et al. Affective comorbidity in panic disorder: is there a bipolar connection? J Affect Disord 1993;28(3):155-63
29. Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2011;26(4):221-4
30. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(5):403-39
31. Gomes de Alvarenga P, de Mathis MA, Dominguez Alves AC, et al. Clinical features of tic-related obsessive-compulsive disorder: results from a large multicenter study. CNS Spectr 2012;17(2):87-93
32. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2013;16(3):557-74
33. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11(7):622-32
34. Roessner V, Schoenefeld K, Buse J, et al. Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology 2013;68:143-9
35. Ducasse D, Boyer L, Michel P, et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology (Berl) 2014;231(18):3765-70
36. Masi G, Pfanner C, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psychiatr Res 2013;47(8):1007-12
37. Costa CDL, Assunc¸ão CM, Ferrão AY, et al. Body dysmorphic disorder in patients with obsessive-compulsive disorder: prevalence and clinical correlates. Depress Anxiety 2012;29(11):966-75
38. Somashekar B, Jainer A, Wuntakal B. Psychopharmacotherapy of somatic symptoms disorders. Int Rev Psychiatry 2013;25(1):107-15
39. Mancuso SG, Knoesen NP, Castle DJ. Delusional versus nondelusional body dysmorphic disorder. Compr Psychiatry 2010;51(2):177-82
40. Odlaug BA, Grant JD. Pathologial skin picking. Am J Drug Alcohol Abuse 2010;36:296-303
41. Lovato L, Ferrão YA, Stein DJ, et al. Skin picking and trichotillomania in adults with obsessive-compulsive disorder. Compr Psychiatry 2012;53(5):562-8
42. Grant JE, Odlaug BL, Kim SW. Nacetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009;66(7):756-63
43. Figee M, Vink M, de Geus F, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol Psychiatry 2011;69(9):867-74
44. Blom RM, Koeter M, van den Brink W, et al. Co-occurrence of obsessivecompulsive disorder and substance use disorder in the general population. Addiction 2011;106(12):2178-85
45. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008;18(6):455-61
46. Khazaal Y, Krenz S, Benmebarek M, Zullino DF. Worsening of obsessive-compulsive symptoms under methadone tapering. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(7):1350-2
47. Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 2013;47(2):175-80
48. Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) 2013;228(4):633-40
49. Sani G, Serra G, Kotzalidis GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012;26(8):663-90
50. Grant JE, Chamberlain SR, Odlaug BL, et al. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) 2010;212(4):603-12
51. Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012;32(6):797-803
52. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184(2):254-6
53. Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol 2014;24(3):375-80
54. Simpson HB, Wetterneck CT, Cahill SP, et al. Treatment of obsessive-compulsive disorder complicated by comorbid eating disorders. Cogn Behav Ther 2013;42(1):64-76
55. Frost RO, Steketee G, Tolin DF. Comorbidity in hoarding disorder. Depress Anxiety 2011;28:876-84
56. Sheppard B, Chavira D, Azzam A, et al. ADHD prevalence and association with hoarding behaviors in childhood-onset OCD. Depress Anxiety 2010;27:667-7
57. Fullana MA, Vilagut GV, Mataix-Cols D, et al. Is ADHD in childhood associated with lifetime hoarding symptoms? An epidemiological study. Depress Anxiety 2013;30:741-8
58. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009;70(11):1530-5
59. Vulink NC, Denys D, Westemberg HG. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixeddose study. J Clin Psychiatry 2005;66(2):228-30
60. Denys D, de Vries F, Cath D, et al. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol 2013;23(11):1423-31
61. Grassi G, Poli L, Cantisani A, et al. Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS Spectr 2013. [Epub ahead of print]
62. Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 2012;10(1):88-95
63. de Haan L, Dudek-Hodge C, Verhoeven Y, Denys D. Prevalence of psychotic disorders in patients with obsessive-compulsive disorder. CNS Spectr 2009;14(8):415-17
64. Nicholson TR, Ferdinando S, Krishnaiah RB, et al. Prevalence of antibasal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. Br J Psychiatry 2012;200(5):381-6
65. van Steense FJ, Bogels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev 2011;14(3):302-17
66. Mito H, Matsuura N, Mukai K, et al. The impacts of elevated autism spectrum disorder traits on clinical and psychosocial features and long-term treatment outcome in adult patients with obsessive-compulsive disorder. Compr Psychiatry 2014. [Epub ahead of print]
67. Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Harv Rev Psychiatry 2014;22(2):76-92
68. Insel T. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry 2014;171:4
69. •• This is a relevant paper on precision medicine in psychiatry.
70. Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008;321(5887):421-2